Cargando…
Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
Human epidermal growth factor receptor 2 (HER2) signaling pathway activation has been identified as a contributor to de novo or acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in a small subset of patients with metastatic colorectal cancer (mCRC). Dual anti-HER2-targeted tr...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163141/ https://www.ncbi.nlm.nih.gov/pubmed/30294606 http://dx.doi.org/10.12998/wjcc.v6.i11.418 |